ANMCO/SIMEU共识文件:正在出血或高出血风险患者抗血栓治疗逆转剂的使用
该共识由意大利医院心脏病学会(ANMCO)与意大利急诊医学会(SIMEU)联合制定,针对动脉粥样硬化、心房颤动和静脉血栓栓塞症患者抗血栓治疗相关的出血并发症。文件概述了近年来开发的抗血栓药物特异性逆转剂,指出这些药物在小规模药效学研究和临床试验中显示有效,但强调需在逆转抗血小板或抗凝治疗的获益与促血栓效应风险之间取得平衡,后者包括抗血栓保护丧失以及出血、大手术或创伤相关的促血栓倾向。共识还提供了实用流程图,指导活动性出血或高出血风险患者中逆转剂的使用。
要点
- 抗血栓药物特异性逆转剂在小规模药效学研究和临床试验中显示有效。
- 逆转抗血小板或抗凝治疗时需权衡获益与促血栓效应风险,包括抗血栓保护丧失和出血、大手术或创伤相关的促血栓倾向。
- 共识由意大利医院心脏病学会(ANMCO)与意大利急诊医学会(SIMEU)联合制定。
- 文件提供实用流程图,指导活动性出血或高出血风险患者中逆转剂的使用。
适用人群与场景
- 正在接受抗血栓治疗且发生活动性出血的患者
- 正在接受抗血栓治疗且处于高出血风险的患者
处置流程与药物剂量
- 共识提供实用流程图指导活动性出血或高出血风险患者中逆转剂的使用;具体流程步骤原文未以条目形式列出。
研究设计与关键结果
- 制定机构:意大利医院心脏病学会(ANMCO)与意大利急诊医学会(SIMEU)联合文件。
- 方法:阐述可用逆转剂的关键特性与疗效,并提供活动性出血或高出血风险患者的使用流程图。
证据类型、等级与局限
- 证据类型:学会联合共识文件。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识强调逆转抗血小板或抗凝治疗时需平衡获益与促血栓效应风险,包括抗血栓保护丧失及出血、大手术或创伤相关的促血栓倾向。
- 共识提供流程图以指导活动性出血或高出血风险患者中逆转剂的使用。
指南或共识出处
- ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events(欧洲心脏杂志增刊 Eur Heart J Suppl)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In recent decades, an incredible evolution in antithrombotic therapies used for treating patients with atherosclerosis, atrial fibrillation, and venous thromboembolism has been observed, leading to the availability of increasingly safe drugs. Nonetheless, bleeding complications remain a significant concern, with considerable health, social, and economic implications. To improve the acute management of patients experiencing or at risk for major bleeding events, specific reversal agents for antithrombotic drugs have been recently developed. While these agents demonstrate effectiveness in small-scale pharmacodynamic studies and clinical trials, it is imperative to balance the benefits of reversing antiplatelet or anticoagulant therapy against the risk of prothrombotic effects. These risks include the potential loss of antithrombotic protection and the prothrombotic tendencies associated with bleeding, major surgery, or trauma. This joint document of the Italian Association of Hospital Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri) and the Italian Society of Emergency Medicine (Società Italiana di Medicina d'Emergenza-Urgenza) delineates the key features and efficacy of available reversal agents. It also provides practical flowcharts to guide their use in patients with active bleeding or those at elevated risk of major bleeding events.
参考来源
- De Luca L, Pugliese FR, Susi B, et al. ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events. Eur Heart J Suppl. 2024. PMID: 38784674. doi:10.1093/eurheartjsupp/suae033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。